ווטריינט 200 מג ישראל - עברית - Ministry of Health

ווטריינט 200 מג

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 200 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

ווטריינט 400 מג ישראל - עברית - Ministry of Health

ווטריינט 400 מג

novartis israel ltd - pazopanib as hydrochloride - טבליות מצופות פילם - pazopanib as hydrochloride 400 mg - pazopanib - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

וטבנציד וטרינרי ישראל - עברית - Ministry of Health

וטבנציד וטרינרי

a.veterinary supply ltd - praziquantel - תמיסה להזרקה - praziquantel 56.8 mg/ml

דרונטל טבליות לחתול וטרינרי ישראל - עברית - Ministry of Health

דרונטל טבליות לחתול וטרינרי

lidorr elements ltd - praziquantel; pyrantel embonate - טבליה - praziquantel 20 mg; pyrantel embonate 230 mg

פרזיטל וטרינרי טבליות לחתולים ישראל - עברית - Ministry of Health

פרזיטל וטרינרי טבליות לחתולים

a.l. medi-market ltd. - praziquantel; pyrantel embonate - טבליה - praziquantel 20 mg; pyrantel embonate 230 mg

אי-קווסט פרמוקס וטרינרי ישראל - עברית - Ministry of Health

אי-קווסט פרמוקס וטרינרי

zoetis israel holding b.v., israel - moxidectin; praziquantel - ג'ל - moxidectin 1.95 %w/w; praziquantel 12.17 %w/w - equest pramox veterinary is indicated for treatment of mixed cestodes and nematodes or arthropods infections, caused by moxidectin and praziquantel sensitive strains of : large strongyles, small strongyles (adults and intraluminal larval stages), ascarids and other species, tapeworm (adults). the egg reappearance period of small strongyles is 90 days. the product is effective against (developing) intramucosal l4 stages of small strongyles. at 8 weeks after treatment, early (hypobiotic) el3 stages of small strongyles are eliminated.

GAZELLE ישראל - עברית - Ministry of Health

gazelle

a.m.i. technologies, ltd. - מומחה - coronary stent system

מילפרו 12.5 מג  125 מג וטרינרי ישראל - עברית - Ministry of Health

מילפרו 12.5 מג 125 מג וטרינרי

vetmarket ltd, israel - milbemycin oxime; praziquantel - טבליות מצופות פילם - praziquantel 125 mg; milbemycin oxime 12.5 mg

ווטריינט 200 מ"ג ישראל - עברית - Ministry of Health

ווטריינט 200 מ"ג

glaxo smith kline (israel) ltd - pazopanib as hydrochloride 200 mg - film coated tablets - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

ווטריינט 400 מ"ג ישראל - עברית - Ministry of Health

ווטריינט 400 מ"ג

glaxo smith kline (israel) ltd - pazopanib as hydrochloride 400 mg - film coated tablets - pazopanib - renal cell carcinoma (rcc)votrient is indicated in adults for the first line treatment of advanced renal cell carcinoma (rcc) and for patients who have received prior cytokine therapy for advanced disease.soft tissue sarcoma (sts)votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft tissue sarcoma (sts) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.